Other substances

CDX-CoV

COVID-19 candidate vaccine

Phase of research

Potential treatment - theoretical effect

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

CDX-CoV is a candidate vaccine being developed by Codagenix/Serum Institute of India. It is a deoptimized live attenuated vaccine. It is based on the Live Attenuated Virus platform, which is also used for non-COVID-19 candidates, such as HAV, InfA, ZIKV, FMD, SIV, RSV, and DENV. Currently, this COVID-19 candidate vaccine is in pre-clinical evaluation.

CDX-CoV on Codagenix

 

 

Supporting references

Link Tested on Impact factor Notes Publication date
DRAFT landscape of COVID-19 candidate vaccines – 26 March 2020
in vitro Mar/26/2020
Export (.csv)